1	Impact of Synchronized Left Ventricular Pacing in Cardiac Resynchronization Therapy
2	Yuichiro Miyazaki ^{1, 2} , Kohei Ishibashi ^{*1} , Nobuhiko Ueda ¹ , Satoshi Oka ^{1, 2} , Akinori
3	Wakamiya ¹ , Keiko Shimamoto ¹ , Kenzaburo Nakajima ¹ , Tsukasa Kamakura ¹ , Mitsuru Wada ^{1,}
4	² , Yuko Inoue ¹ , Koji Miyamoto ¹ , Satoshi Nagase ¹ , Takeshi Aiba ¹ , Kengo Kusano ^{1, 2}
5	
6	¹ Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita,
7	Japan
8	² Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences,
9	Kumamoto University, Kumamoto, Japan
10	Short title: Synchronized left ventricular pacing in CRT
10 11	Short title: Synchronized left ventricular pacing in CRT *Correspondence:
11	*Correspondence:
11 12	*Correspondence: Kohei Ishibashi, MD, PhD
11 12 13	*Correspondence: Kohei Ishibashi, MD, PhD Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1
11 12 13 14	*Correspondence: Kohei Ishibashi, MD, PhD Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan
11 12 13 14 15	*Correspondence: Kohei Ishibashi, MD, PhD Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan Tel: +81-6-6170-1070
11 12 13 14 15 16	*Correspondence: Kohei Ishibashi, MD, PhD Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan Tel: +81-6-6170-1070 Fax: +81-6-6170-1348

20 Abstract

Background: The adaptive cardiac resynchronization therapy (aCRT) algorithm enables synchronized left ventricular pacing (sLVP) to produce fusion with intrinsic right ventricular activation in normal atrioventricular (AV) conduction. Although sLVP presents benefits over biventricular pacing (BVP), the adequate sLVP rate for better clinical outcomes remains unclear. This study aimed to assess the association between sLVP rates and clinical outcomes.

Methods: Among our cohort of 271 consecutive patients who underwent CRT implantation between April 2016 and August 2021, we evaluated 63 patients who underwent CRT without considerably prolonged AV conduction and applied the aCRT algorithm (48 men, mean age: 64 \pm 14 years; median follow-up period: 316 days [interquartile range: 212–809 days]).

30 **Results:** At the 6-month follow-up after CRT implantation, the frequency of CRT responders 31 was 71% (n = 45). The sLVP rate was significantly higher in responders than in non-responders 32 $(75 \pm 30 \text{ vs. } 47 \pm 40 \text{ \%}, p = 0.003)$. Receiver operating characteristics (ROC) curve analysis 33 revealed that the optimal cut-off value during the sLVP rate was 59.4% for prediction of CRT 34 responders (area under the curve, 0.70; sensitivity, 80%; specificity, 61%; positive predictive 35 value, 84%; and negative predictive value, 55%). Kaplan–Meier analysis demonstrated that the 36 higher sLVP group (sLVP \geq 59.4%, n = 43) had better prognosis (cardiac death and heart failure 37 hospitalization) than the lower sLVP group (sLVP <59.4%, n = 20) (log-rank p<0.001), and 38 multivariate Cox hazard analysis revealed that a higher sLVP rate was associated with good 39 prognosis (*p*<0.001).

40 Conclusion: sLVP was associated with CRT response, and higher sLVP rate (≥59.4%) is
41 important for good prognosis in patients with aCRT.

43 KEYWORDS

44 Adaptive CRT, cardiac resynchronization therapy, left ventricular pacing, responder

45

46 CLINICAL PERSPECTIVE

47 What Is New?

- 48 Synchronized left ventricular pacing(sLVP) >59.4% was a significant predictor of cardiac
- 49 resynchronization therapy(CRT) responders and better clinical outcomes, evidenced by the
- 50 results of the multivariate analysis.
- In this study, which included patients with moderately prolonged PR intervals, high sLVP
- 52 rates were associated with better clinical outcomes.

53 What Are the Clinical Implications?

- sLVP rate was associated with the improvement of cardiac function after CRT implantation.
- A higher sLVP rate was associated with a lower risk of cardiac death and heart failure
- 56 hospitalization.

57

58 LIST OF ABBREVIATIONS

- 59 aCRT: Adaptive cardiac resynchronization therapy
- 60 AV: Atrioventricular
- 61 BVP: Biventricular pacing
- 62 ECG: Electrocardiogram
- 63 HF: Heart failure
- 64 ICM: Ischaemic cardiomyopathy

- 65 LBBB: Left bundle branch block
- 66 LVEF: Left ventricular ejection fraction
- 67 LVESV: Left ventricular end-systolic volume
- 68 NYHA: New York Heart Association
- 69 ROC: Receiver operating characteristics
- 70 SPECT: Single-photon emission computed tomography
- 71 sLVP: Synchronized left ventricular pacing
- 72 VV: Interventricular

73 1 INTRODUCTION

74 Cardiac resynchronization therapy (CRT) improves cardiac function and clinical outcomes in 75 patients with symptomatic heart failure accompanied by decreased left ventricular ejection 76 fraction (LVEF), QRS prolongation, and left bundle branch block (LBBB) (1). However, up to 77 30% of patients do not see improvements in cardiac function and/or clinical prognosis after 78 CRT implantation (2). The Adaptive CRT algorithm (aCRT) is a novel pacing algorithm for 79 CRT that continuously optimises the atrioventricular (AV) and the interventricular (VV) 80 delays based on heart rate and intrinsic AV conduction (3). In cases whereby the AV interval is 81 shorter than 220 ms (during atrial sensing) or 270 ms (during atrial pacing), the aCRT 82 algorithm uses the RV intrinsic conduction, which can provide synchronized left ventricular 83 pacing (sLVP) to create fusion beat with the intrinsic conduction. In cases where the AV 84 interval is extremely prolonged, the aCRT pacing provides biventricular pacing (BVP) 85 without fusion with the intrinsic conduction. The sLVP was reported to have benefits over 86 BVP regarding the risk of heart failure (HF), hospitalization, cardiac death, or atrial 87 fibrillation (4,5). However, the adequate sLVP rate for better clinical outcomes remains unclear. This novel study aimed to assess the appropriate sLVP rate for recovering cardiac 88 89 function in the mid-term, and to improve clinical outcomes in the long-term.

90

91 **2 METHODS**

92 2.1 Study population

93 This retrospective single-centre study included all consecutive patients who underwent CRT 94 device implantation featuring the Adaptive CRT algorithm (Medtronic Inc., Minneapolis, MN, 95 USA) (aCRT) between April 1, 2016, and August 31, 2021. The aCRT pacing mode was 96 adapted just after the implantation. Patients who applied the pacing algorithm without adopting 97 sLVP mode were excluded from this analysis. In addition, patients with persistent atrial

98 fibrillation, AV block, and extremely prolonged PR also were excluded from this analysis, due99 to difficulty in using sLVP.

100

101 This study was conducted in accordance with the principles outlined in the Declaration of 102 Helsinki and approved by the ethics committee of our institution (M26-150-10). This is a 103 retrospective study to analyze the anonymous data generated after patients have agreed to 104 treatment; we applied the opt-out method to obtain informed consent.

105

106 **2.2** Study protocol

107 The patients enrolled in this study were classified into two groups (CRT responder or 108 non-responder) depending on the response to CRT pacing 6 months after CRT implantation. 109 Next, we determined the required sLVP rate to become a CRT responder using a receiver 110 operating characteristic (ROC) curve analysis. Thereafter, we compared the association 111 between the sLVP rate and clinical prognosis.

112

113 2.3 Cardiac examinations and definition of responses before and after CRT 114 implantation

115 Cardiac systolic function was assessed using both echocardiography and single-photon 116 emission computed tomography (SPECT) before and 6 months after CRT device implantation. 117 Electrocardiogram (ECG)-gated myocardial perfusion SPECT imaging with technetium-99m 118 (^{99m}Tc) sestamibi was performed to measure cardiac systolic function and dimensions. All 119 echocardiographic data were measured during three consecutive cardiac cycles. The left 120 ventricular end-systolic volume (LVESV) and LVEF were measured using Simpson's biplane 121 method.

122 CRT responders were described as patients with an improved LVEF >10% and/or reduced

123	LVESV >15% 6 months after CRT device implantation compared with baseline. Cardiac death
124	and/or hospitalization for HF were evaluated as clinical outcomes. Cardiac death was defined
125	as HF death, left ventricular assist device implantation, or death from ventricular arrhythmia.
126	HF hospitalization was defined as a sudden or gradual onset of symptoms of New York Heart
127	Association (NYHA) functional class III or IV HF, requiring unplanned hospitalization.

128

129 2.4 Statistical analyses

130 Data were analyzed using JMP software (version 11.2.01, SAS Institute, Cary, NC, USA). 131 Continuous variables are presented as mean \pm standard deviation and were compared using 132 Student's *t*-test. Categorical variables were compared using Fisher's exact test. The cumulative 133 incidence and event-free curves were based on Kaplan-Meier analyses, stratified by study 134 group, and contrasted using the log-rank test. Hazard ratios and odds ratios are reported with 135 their 95% confidence intervals. To identify independent predictors of clinical response, 136 univariable analyses were first performed, and predictors with a significance level <5%, age, 137 and sex were included in the multivariable models. Multivariable analyses were performed 138 using a Cox regression model. *P*-values of <0.05 were considered reflective of statistically 139 significant differences.

140

141 **3 RESULTS**

142 **3.1** Patient characteristics

Among our cohort of 271 consecutive patients who underwent CRT implantation between April 2016 and August 2021, we evaluated 63 patients who underwent CRT without considerably prolonged AV conduction on whom we applied the aCRT algorithm (48 men, mean age: 64 ± 14 years) (Figure 1). The baseline characteristics of the patients are shown in Table 1. The number of patients with ischaemic cardiomyopathy (ICM) was 17 (27%), and

148 mean LVEF was $23 \pm 7\%$. Mean PR and QRS time were 192 ± 32 ms and 155 ± 25 ms, 149 respectively, and the number of patients with LBBB was 31 (49%).

150

151 **3.2** CRT responder and synchronized left ventricular pacing rate

152 At the 6-month follow-up after CRT implantation, the frequency of CRT responders was 71% 153 (n = 45) (Table 1). Patients with LBBB were significantly more frequent than those without. 154 There was no significant difference in the QRS width and rate of ICM. The sLVP rate was 155 significantly higher in responders than in non-responders (75 ± 30 vs. $47 \pm 40\%$, p = 0.003). 156 ROC curve analysis revealed that the optimal cut-off value during sLVP rate was 59.4% for the 157 prediction of CRT responders (area under the curve, 0.71; sensitivity, 80%; specificity, 61%; 158 positive predictive value, 84%; and negative predictive value, 55%) (Figure 2). Multivariate 159 analysis showed that sLVP >59.4% was an independent responder for CRT responder (odds 160 ratio: 4.52, 95% CI: 1.18–18.90, p = 0.027) (Table 2).

161

162 **3.3** Clinical outcome of high sLVP rate

During a median follow-up of 346 days (IQR, 223–760 days), one patient had cardiac death and 13 patients had HF hospitalizations. Five patients died during hospitalization because of HF. Kaplan–Meier analysis demonstrated that the high sLVP group (sLVP \geq 59.4%, n = 43) had a better prognosis (cardiac death and HF hospitalization) than the low sLVP group (sLVP <59.4%, n = 20) (log-rank *p*<0.001) (Figure 3), and multivariate Cox hazard analysis revealed that higher sLVP rate was associated with good prognosis (hazard ratio: 0.10, 95% CI: 0.01– 0.40, *p* = 0.027, *p*<0.001) (Table 3).

170

172 4 **DISCUSSION**

173 Main findings

- 174 The main findings of this study are as follows: (1) CRT responders had higher sLVP rates than
- 175 CRT non-responders, (2) sLVP >59.4% was an excellent predictor of CRT response, and (3)
- 176 sLVP >59.4% led to fewer cardiac deaths and hospitalizations due to HF.
- 177

178 The mechanism of fusion beat of pacing and intrinsic conduction

179 Recent CRT devices have the function to automatically adjust the fusion beat of self AV 180 conduction and pacing. This regulatory function seems to lead to further narrowing of the QRS 181 width after the CRT implantation (6). Previous studies have reported that the narrowing of QRS 182 width after the CRT implantation can improve echocardiographic outcomes and long-term 183 mortality (7,8). In addition to the function of adjusting the fusion beat, other studies have 184 reported that sLVP could shorten QRS width compared with BVP (9,10). The sLPV may 185 contribute to improved responder rate and better clinical outcomes by achieving QRS 186 narrowing by creating the fusion beat with the intrinsic waveform and pacing.

187

188 The adequate frequency of synchronized left ventricular pacing

189 Adaptive CRT has an automatic adjustment algorithm for AV and interventricular delays based 190 on frequent AV conduction evaluations. Furthermore, sLVP is often used for normal AV 191 conduction (9). A previous study showed that sLVP provided better clinical outcomes than 192 conventional BVP (4); however, the frequency of sLVP that leads to a better prognosis is not 193 well known. Previous studies have defined the cut-off rate of sLVP to be 80% to predict clinical 194 and echocardiographic parameters (9). Another study reported that an sLVP rate >50% was 195 associated with better clinical outcomes compared with that of <50% (4). However, these rates 196 are not statistically determined values. In this study, sLVP >59.4% was a significant predictor

of CRT responders and better clinical outcomes, evidenced by the results of the multivariate
analysis. Using this criterion, we may be able to predict clinical responses, such as cardiac
death and HF hospitalization.

200

201 The association between synchronized left ventricular pacing and PR interval

202 A previous study reported that LVP improved LV dp/dt max in patients with a PR interval <200 203 ms (11). Other studies have also reported the effect of sLVP in patients with a normal PR 204 interval (9,10); however, the significance of sLVP in patients with prolonged PR intervals is 205 unknown. In this study, which included patients with moderately prolonged PR intervals, high 206 sLVP rates were associated with better clinical outcomes. However, the patients with sLVP 207 <59.4% had longer PR intervals than the patients with sLVP >59.4%. The sLVP rate appeared 208 significantly affected by PR interval, especially in patients with prolonged PR intervals. 209 Prolonged PR intervals are considered a significant factor in preventing a high sLVP rate. A 210 previous report showed that RA septal pacing was associated with a shorter AV interval than 211 right appendage pacing (12). The case report demonstrated that the sLVP rate was increased by 212 RA septal pacing in patients with extremely prolonged PR intervals (424 ms). In this study, 213 most patients experienced right appendage pacing. We should consider that the RA pacing lead 214 is positioned at the RA septum in patients with a prolonged PR interval to increase the LPV 215 rate.

216

217 5 STUDY LIMITATIONS

This study had some limitations. First, this was a retrospective single-centre study. The results of this study should be further confirmed by prospective and multi-centre studies in the future.
Second, the sample size was small, which reduces the statistical strength of our findings. In order to resolve this point, it is necessary to collect cases in a multi-center study. Third, the

222	current study	compared t	the mixture	of sLVP	and BVP.	To clarify	the effect	of the sLVP, w	ve
-----	---------------	------------	-------------	---------	----------	------------	------------	----------------	----

- 223 have to compare the pure sLVP and the pure BVP.
- 224

225 6 CONCLUSIONS

- 226 Our study shows that the sLVP rate is associated with the CRT responder rate. A higher sLVP
- rate (>59.4 %) is associated with a lower risk of cardiac death and HF hospitalization.

228

- 229 Data Availability: The datasets generated and/or analyzed during the current study are
- available from the corresponding author upon reasonable request.

231

- 232 Sources of Funding: This research did not receive any specific grants from funding agencies
- 233 in the public, commercial or not-for-profit sectors.

234

235 Disclosures: None.

237 **REFERENCES**

- Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ,
 Packer M, Clavell AL, Hayes DL, et al. Cardiac Resynchronization in Chronic
 Heart Failure. *New England Journal of Medicine*. 2002;346:1845–1853.
- 241 2. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, Guida P,
 242 Andriani A, Mastropasqua F, Rizzon P. Cardiac Resynchronization Therapy
 243 Tailored by Echocardiographic Evaluation of Ventricular Asynchrony. *Journal of* 244 *the American College of Cardiology*. 2002;40:1615–1622.
- Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, Gasparini M,
 Starling RC, Milasinovic G, Rogers T, et al. Investigation of a Novel Algorithm
 for Synchronized Left-Ventricular Pacing and Ambulatory Optimization of
 Cardiac Resynchronization Therapy: Results of the Adaptive CRT Trial. *Heart Rhythm.* 2012;9:1807–1814.
- Birnie D, Lemke B, Aonuma K, Krum H, Lee KL, Gasparini M, Starling RC,
 Milasinovic G, Gorcsan J, Houmsse M *et al.* Clinical Outcomes with
 Synchronized Left Ventricular Pacing: Analysis of the Adaptive CRT Trial. *Heart Rhythm.* 2013;10:1368–1374.
- Hsu JC, Birnie D, Stadler RW, Cerkvenik J, Feld GK, Birgersdotter-Green U.
 Adaptive Cardiac Resynchronization Therapy Is Associated with Decreased Risk
 of Incident Atrial Fibrillation Compared to Standard Biventricular Pacing: A
 Real-World Analysis of 37,450 Patients Followed by Remote Monitoring. *Heart Rhythm.* 2019;16:983–989.
- Thibault B, Ritter P, Bode K, Calò L, Mondésert B, Mangual JO, Badie N,
 McSpadden LC, Pappone C, Varma N. Dynamic Programming of Atrioventricular
 Delay Improves Electrical Synchrony in a Multicenter Cardiac Resynchronization

262 Therapy Study. *Heart Rhythm*. 2019;16:1047–1056.

- Jastrzębski M, Baranchuk A, Fijorek K, Kisiel R, Kukla P, Sondej T, Czarnecka D.
 Cardiac Resynchronization Therapy-Induced Acute Shortening of QRS Duration
 Predicts Long-Term Mortality Only in Patients with Left Bundle Branch Block.
 Europace. 2019;21:281–289.
- 8. Hsing JM, Selzman KA, Leclercq C, Pires LA, Mclaughlin MG, Mcrae SE,
 Peterson BJ, Zimetbaum PJ. Paced Left Ventricular QRS Width and ECG
 Parameters Predict Outcomes after Cardiac Resynchronization Therapy:
 PROSPECT-ECG Substudy. *Circulation. Arrhythmia and Electrophysiology*.
 2011;4:851–857.
- Burns KV, Gage RM, Curtin AE, Gorcsan III J, Bank AJ. Left Ventricular-Only
 Pacing in Heart Failure Patients with Normal Atrioventricular Conduction
 Improves Global Function and Left Ventricular Reginal Mechanics Compared
 with Biventricular Pacing: an Adaptive Cardiac Resynchronisation Therapy
 Sub-study. *European Journal of Heart Failure*. 2017;29:1335–1343.
- 277 10. Su Y, Hua W, Shen F, Zou J, Tang B, Chen K, Liang Y, He L, Zhou X, Zhang X, et
 278 al. Left Ventricular-Only Fusion Pacing versus Cardiac Resynchronization
 279 Therapy in Heart Failure Patients: A Randomized Controlled Trial. *Clinical*280 *Cardiology*. 2021;44:1225–1232.
- 11. Van Gelder BM, Bracke FA, Meijer A, Pijls NH. The Hemodynamic Effect of
 Intrinsic Conduction during Left Ventricular Pacing as Compared to Biventricular
 Pacing. *Journal of the American College of Cardiology*. 2005;46:2305–2310.
- Murata Y, Ishibashi K, Yamagata K, Izumi C, Noguchi T, Kusano K. Impact of
 Atrial Septal Pacing in Left Ventricular-Only Pacing in Patients with a
 First-Degree Atrioventricular Block: A Case Series. *HeartRhythm Case Reports*.

287 2022;8:187–190.

288 TABLES

289

290 Table 1. Baseline characteristics between responders and non-responders

	All patients $(n = 63)$	Responder ($n = 45$)	Non-responder (<i>n</i> =	<i>P</i> -Val	
			18)	ue	
Age, years	64 ± 14	65 ± 13	63 ± 15	P	=
				0.586	
Men	48 (76%)	34 (76%)	14 (78%)	P	>
				0.999	
Height, cm	166 ± 9	166 ± 9	166 ± 9	P	=
				0.984	
Body	61 ± 13	63 ± 12	57 ± 14	P	=
weight, kg				0.093	
CRT-D/CRT	56/7	38/7	18/0	P	=
-P				0.177	
Secondary	10 (16%)	5 (11%)	5 (28%)	P	=
prevention				0.132	
NYHA,	44(70%)/15(24%)/4(32(71%)/11(24%)/2(12(67%)/4(22%)/2(1	P	=
II/III/IV	6%)	4%)	1%)	0.617	
ICM	17 (27%)	9 (20%)	8 (44%)	P	=
				0.063	
HT	23 (37%)	19 (42%)	4 (22%)	P	=
				0.159	
DM	18 (29%)	15 (33%)	3 (17%)	P	=

				0.230
CKD	31 (49%)	21 (47%)	10 (56%)	<i>P</i> =
				0.585
LVEF, %	23 ± 7	22 ± 7	24 ± 8	<i>P</i> =
				0.386
LVESV, mL	181 ± 80	178 ± 84	190 ± 70	<i>P</i> =
				0.630
PR time, ms	192 ± 32	188 ± 31	204 ± 34	<i>P</i> =
				0.084
QRS time,	155 ± 25	159 ± 27	146 ± 18	<i>P</i> =
ms				0.057
LBBB	31 (49%)	27 (60%)	4 (22%)	<i>P</i> =
				0.011
LV only	67 ± 35	75 ± 30	47 ± 40	<i>P</i> =
pacing, %				0.003
Cre, mg/dL	1.2 ± 0.6	1.2 ± 0.7	1.2 ± 0.4	<i>P</i> =
				0.817
BNP, pg/mL	401 ± 473	352 ± 474	525 ± 459	<i>P</i> =
				0.1913

291 Data are presented as the mean \pm standard deviation or number (percentage).

Abbreviations: BNP, brain natriuretic peptide; CKD, chronic kidney disease; Cre, creatinine;
CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization
therapy pacemaker; DM, diabetes mellitus; HT, hypertension; ICM, ischaemic
cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume; NICM, non-ischaemic cardiomyopathy; NYHA,

297 New York Heart Association.

	Univariate analysis			Multivariate analysis			
	OR	95% CI	<i>P</i> -value	OR	95% CI	<i>P</i> -value	
ge, 1 year	0.98	0.94–1.02	0.580	0.98	0.93-1.03	0.647	
ncrease							
Ien	0.88	0.21-3.09	0.850	0.65	0.12–2.92	0.589	
СМ	0.31	0.09–1.02	0.054				
IT	2.55	0.77-10.13	0.126				
DM	2.50	0.68–11.99	0.170				
KD	0.70	0.22-2.09	0.523				
VEF, 1%	1.03	0.95–1.11	0.383				
ncrease							
VESV, 1 mL	1.00	0.99–1.00	0.631				
ncrease							
R, 1 ms	1.01	0.99–1.03	0.081				
ncrease							
QRS, 1 ms	0.97	0.95-1.00	0.051				
ncrease							
BBB	5.25	1.59–20.91	0.005	2.81	0.68-12.76	0.149	
LVP>59.4%	6.28	1.95–21.91	0.001	4.52	1.18–18.90	0.027	
ncrease BBB							

299 Table 2. Univariate and multivariate analyses for responder

Abbreviations: BNP, brain natriuretic peptide; CI, confidence interval; CKD, chronic kidney
disease; DM, diabetes mellitus; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB,
left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular
end-systolic volume; OR, odds ratio; sLVP, synchronized left ventricular pacing.


304 Table 3. Univariate and multivariate analyses for cardiac death and heart failure

305 hospitalization

	Univar	iate analysis		Multivariate analysis			
	HR	95% CI	<i>P</i> -value	HR	95% CI	<i>P</i> -value	
Age, 1 year	0.99	0.96–1.04	0.972	0.95	0.90-1.00	0.061	
increase							
Men	0.68	0.22–2.53	0.541	0.63	0.15–2.88	0.541	
ICM	2.51	0.82-7.32	0.102				
HT	0.28	0.04–1.03	0.055				
DM	1.00	0.27-3.04	0.999				
CKD	3.72	1.23–13.72	0.019	14.51	2.79–108.45	< 0.001	
LVEF, 1%	0.97	0.89–1.04	0.521				
increase							
LVESV, 1 mL	1.00	0.99–1.00	0.994				
increase							
PR, 1 ms	1.01	0.99–1.03	0.060				
increase							
QRS, 1 ms	0.98	0.96–1.00	0.149				
increase							
LBBB	0.26	0.05–0.84	0.023	0.41	0.08-1.55	0.198	
sLVP>59.4%	0.12	0.02–0.40	< 0.001	0.10	0.01–0.40	< 0.001	

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus;
HR, hazard ratio; HT, hypertension; ICM, ischaemic cardiomyopathy; LBBB, left bundle
branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic
volume; sLVP, synchronized left ventricular pacing.

310 FIGURES




312 Figure 1. Overview of the study population

- 313 Among our cohort of 271 consecutive patients who underwent CRT implantation between
- 314 April 2016 and August 2021, we evaluated 63 sLPV enabled CRT patients and applied the

315 aCRT algorithm.

- 316 Abbreviations: AF, atrial fibrillation; AV, atrioventricular; CRT, cardiac resynchronization
- 317 therapy; sLVP, synchronized left ventricular pacing.




318

319 Figure 2. The association between CRT responder and synchronized left ventricular

320 pacing rate

- 321 Receiver operating characteristic curve analysis revealed that the optimal cut-off value during
- 322 sLVP rate was 59.4% for the prediction of CRT responders.
- 323 Abbreviations: CRT, cardiac resynchronization therapy; sLVP, synchronized left ventricular
- 324 pacing
- 325





328

Figure 3 Kaplan–Meier analysis. The analysis demonstrates that the higher sLVP group (sLVP>59.4%, n = 43) had better prognosis (with regard to cardiac death and heart failure hospitalization) than the lower sLVP group (sLVP<59.4%, n = 20) (log-rank p<0.001).

332 Abbreviations: sLVP, synchronized left ventricular pacing.